MDT vs NVCR
MDT: Medtronic is a global healthcare technology leader dedicated to alleviating pain, restoring health, and extending life through innovative medical devices and digital solutions. NVCR: Novocure is an oncology company utilizing proprietary Tumor Treating Fields (TTFields) to disrupt cancer cell division through wearable, non-invasive electric field therapy.
Side-by-side fundamentals
| Metric | MDT | NVCR | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $87.75 | $14.22 | |
| Market cap | $112.2B | $1.7B | |
| P/E as of 2026-10-08 | 23.54 | n/a | |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2026 | 2.41 | n/a | |
| Net margin | +13.2% | -20.8% | MDT higher |
| Gross margin FY2025, SEC XBRL | n/a | +74.5% | |
| Operating margin | +17.8% | -23.5% | MDT higher |
| ROE | +9.7% | -40.0% | MDT higher |
| ROA | +5.2% | -16.9% | MDT higher |
| Debt / equity as of 2026-09-03 | 0.57 | 0.58 | MDT lower |
| Revenue growth (YoY) as of 2026-09-03 | +8.4% | +10.9% | NVCR higher |
| Revenue CAGR (3y) SEC XBRL | +5.2% | +6.8% | NVCR higher |
| Dividend yield as of 2026-09-03 | +3.1% | n/a | |
| Dividend streak (yrs) SEC XBRL | 14 | 0 | MDT higher |
| Beta as of 2026-09-03 | 0.36 | 1.31 | |
| 1-year return as of 2026-10-08 close | -10.3% | -0.9% | NVCR higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.